We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MYOS RENS Technology Inc | NASDAQ:MYOS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.01 | 1.02 | 1.06 | 0 | 01:00:00 |
CEDAR KNOLLS, N.J., March 28, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today its results for the fourth quarter and fiscal year ended December 31, 2018.
MANAGEMENT COMMENTARY:
Joseph Mannello, Chief Executive Officer of MYOS, commented, "Our overall performance in fiscal year 2018 reflected much of the transformation of our business that I referred to in my letter to shareholders in January 2019.
"I discussed our near-term initiatives for positioning our Fortetropin-based product brands to grow our sales. We reached several key milestones on this front in 2018, including the launch of our NSF "Certified for Sport®" sports nutrition brand, Yolked®, along with our pet product MYOS Canine Muscle Formula® ("MYOS Canine"). In less than a year's time, we have expanded our sales opportunities for both brands, and we expect to deliver increased sales in 2019 for these products.
"For our Yolked brand, we've expanded our marketing partnership with IMG in order to introduce Yolked to colleges throughout the country. In addition, our sales partnership with The Vitamin Shoppe® began in earnest in early 2019 to get our Yolked brand on the shelves of their 700+ stores throughout the country. With our revamped website (www.yolked.com) and our in-house sales and marketing initiatives, I'm excited about the potential of Yolked.
"We launched MYOS Canine in June 2018. Since then, we announced our first distribution agreement which will bring greater exposure to veterinary hospitals. The feedback and testimonials we've received from our initial customers on our website www.myospet.com, have been overwhelmingly positive. Together with the encouraging results from our Kansas State University study, which validates our product benefits to veterinarians, I'm very optimistic about the commercial opportunities for our pet business product line in 2019.
"Our long-term initiatives are rooted in our ability to research the clinical uses of Fortetropin to fully leverage its potential and determine our entry-point into the medical nutrition market. We believe these studies and research initiatives will support our ability to build and enhance our patent portfolio and to improve our current product offering with the development of new products. We currently have one clinical and one pre-clinical study underway and anticipate launching additional clinical studies over the next several months. With the compelling results from our Kansas State University study, we feel confident to move forward with a human clinical study related to muscle atrophy after total knee replacement surgery.
"We recently launched our second Kansas State University study, which expands the scope of potential patients from our earlier study to include geriatric dogs experiencing weakness, weight loss, slow mobility, and exercise intolerance. The results of this study will help us to expand our business in the animal health market.
"I expect 2019 will be an important and eventful year for MYOS. We continually evaluate ways to increase our cash runway by controlling expenses and generating cash from increased sales, potential licensing and/or financing transactions. I see a tremendous opportunity for MYOS to capitalize on our attractively positioned brands to create more widespread adoption of our products. We will work diligently to refine our strategic approach to capitalize on opportunities in front of us today, while paving a path towards sustainable profitability over the long term," concluded Mr. Mannello.
CLINICAL RESEARCH HIGHLIGHTS:
BUSINESS & OPERATIONAL HIGHLIGHTS:
FINANCIAL HIGHLIGHTS (Amounts in thousands except where noted.):
Fourth Quarter 2018:
Net sales for the quarter ended December 31, 2018 were $149, a decrease of $8, or 5%, compared to $157 for the quarter ended December 31, 2017.
Cost of sales for the quarter ended December 31, 2018 increased 33% to $97, compared to cost of sales of $64 for the quarter ended December 31, 2017.
Gross profit for the quarter ended December 31, 2018 decreased 45% to $51, compared to $93 for the quarter ended December 31, 2017. Gross profit margin for the quarter ended December 31, 2018 was 34%, compared to 59% for the quarter ended December 31, 2017.
Operating expenses were $1,224 in the quarter ended December 31, 2018, an increase of 5% compared to operating expenses of $1,173 for the quarter ended December 31, 2017.
Net loss decreased 96% to $62 for the quarter ended December 31, 2018 compared to $1,082 for the quarter ended December 31, 2017.
Year Ended December 31, 2018
Net sales for the year ended December 31, 2018 were $360, a decrease of $166, or 32%, compared to $526 for the year ended December 31, 2017 primarily due to net sales of $327 in 2017 of our previous product lines, offset by an increase in sales of $161 in all of our current product lines, including Yolked® and MYOS Canine Muscle Formula®.
Cost of sales for the year ended December 31, 2018 were $248, a decrease of $60 or 19%, compared to cost of sales of $308 for the year ended December 31, 2017, primarily due to lower costs associated with a decrease in direct sales to consumers.
Gross profit for the year ended December 31, 2018 decreased 49% to $112, compared to $218 for the year ended December 31, 2017.
Operating expenses were $4,441 for the year ended December 31, 2018, an increase of 4% compared to operating expenses of $4,286 for the year ended December 31, 2018. This was due to a $72 increase in sales and marketing expenses, primarily for marketing and promotional costs associated with the development and launch of new products in 2018, a $267 increase in personnel and benefits costs, primarily for the hiring of additional sales staff to support the new product launch, and a $183 decrease in general and administrative expenses, due to a decrease in costs associated with legal proceedings.
Net loss decreased $835 or 21% to $3,223 for the year ended December 31, 2018 compared to $4,058 for the year ended December 31, 2017.
Liquidity
As of December 31, 2018, the Company had cash of $15 and total assets of $4,455, and $1,269 in working capital. Net cash used in operating activities for the year ended December 31, 2018 was $3,250, a decrease of $533 compared to $3,783 for the year ended December 31, 2017.
At-the-Market Offering
Subsequent to year end, on January 15, 2019, the Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65, and on March 19, 2019, the Company sold 73,560 shares of common stock for $1.86 per share for gross proceeds of $138.
CONFERENCE CALL
MYOS will host a conference call on Thursday, March 28, 2019 at 11:00 AM ET, at which time MYOS' Chief Executive Officer Joseph Mannello will provide commentary on earnings results and provide an update on the business.
Conference Call Details:
A digital replay will be available by telephone approximately two hours after the completion of the call until June 30, 2019 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, using the Conference ID# 13689169.
This call will be simultaneously webcast. The webcast will be available on the MYOS website, www.myosrens.com, in the "Investor Relations" section. The webcast will be archived and available at the same web address for two weeks following the call.
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the success of our products, including Qurr®, Yolked®, MYOS Enteral Nutrition Formula™ and MYOS Canine Muscle Formula® products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects including the clinical study described herein, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate revenue and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.
The following tables should be read in conjunction with the footnotes accompanying the consolidated financial statements contained within the Annual Report on Form 10-K filed by the Company on March 27, 2019.
MYOS RENS TECHNOLOGY INC. AND SUBSIDIARY Consolidated Balance Sheets (in thousands, except share amounts) | ||||||||
December 31, | December 31, | |||||||
2018 | 2017 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 15 | $ | 923 | ||||
Accounts receivable, net | 78 | 4 | ||||||
Other current asset | 1,124 | - | ||||||
Inventories, net | 1,676 | 1,779 | ||||||
Prepaid expenses | 10 | 113 | ||||||
Total current assets | 2,903 | 2,819 | ||||||
Other asset | 50 | 50 | ||||||
Deferred offering costs | 108 | 102 | ||||||
Fixed assets, net | 149 | 184 | ||||||
Intangible assets, net | 1,245 | 1,640 | ||||||
Total assets | $ | 4,455 | $ | 4,795 | ||||
LIABILITIES AND STOCKHOLDERS' | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 236 | $ | 176 | ||||
Accrued expenses and other current | 383 | 255 | ||||||
Related party promissory note payable and | 1,015 | - | ||||||
Total current liabilities | 1,634 | 431 | ||||||
Total liabilities | 1,634 | 431 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, $.001 par value; 500,000 | - | - | ||||||
Common stock, $.001 par value; | 8 | 6 | ||||||
Additional paid-in capital | 37,880 | 36,202 | ||||||
Accumulated deficit | (35,067) | (31,844) | ||||||
Total stockholders' equity | 2,821 | 4,364 | ||||||
Total liabilities and stockholders' equity | $ | 4,455 | $ | 4,795 |
MYOS RENS TECHNOLOGY INC. AND SUBSIDIARY Consolidated Statements of Operations (in thousands, except per share amounts) | ||||||||
Years Ended | ||||||||
December 31, | ||||||||
2018 | 2017 | |||||||
Net revenues | $ | 360 | $ | 526 | ||||
Cost of sales | 248 | 308 | ||||||
Gross profit | 112 | 218 | ||||||
Operating expenses: | ||||||||
Selling, marketing and research | 894 | 822 | ||||||
Personnel and benefits | 1,718 | 1,450 | ||||||
General and administrative | 1,829 | 2,014 | ||||||
Total operating expenses | 4,441 | 4,286 | ||||||
Operating loss | (4,329) | (4,068) | ||||||
Other (expense) income: | ||||||||
Other (expense) income | (2) | 12 | ||||||
Interest expense | (16) | (2) | ||||||
Total other (expense) income | (18) | 10 | ||||||
Loss before income taxes | (4,347) | (4,058) | ||||||
Income tax benefit | 1,124 | - | ||||||
Net loss | $ | (3,223) | $ | (4,058) | ||||
Net loss per share attributable to common | ||||||||
Basic and diluted | $ | (0.45) | $ | (0.69) | ||||
Weighted average number of common shares | ||||||||
Basic and diluted | 7,139,312 | 5,875,239 |
MYOS RENS TECHNOLOGY INC. AND SUBSIDIARY Consolidated Statements of Cash Flows (in thousands) | ||||||||
Years Ended | ||||||||
December 31, | ||||||||
2018 | 2017 | |||||||
Cash Flows From Operating Activities: | ||||||||
Net loss | $ | (3,223) | $ | (4,058) | ||||
Adjustments to reconcile net loss to net cash used in | ||||||||
Depreciation | 35 | 51 | ||||||
Amortization | 395 | 267 | ||||||
Provision for inventory reserve | 25 | 2 | ||||||
Bad debt expense | - | 59 | ||||||
Share-based compensation | 235 | 160 | ||||||
Deferred offering costs | 97 | - | ||||||
Changes in operating assets and liabilities: | ||||||||
Increase in accounts receivable | (74) | (55) | ||||||
Increase in other current asset | (1,124) | - | ||||||
Decrease in inventories | 78 | 81 | ||||||
Decrease (increase) in prepaid expenses | 103 | (78) | ||||||
Decrease in deferred revenue | - | (56) | ||||||
Decrease in accounts payable and accrued expenses | 203 | (156) | ||||||
Net cash used in operating activities | (3,250) | (3,783) | ||||||
Cash Flows From Investing Activities: | ||||||||
Purchases of fixed assets | - | (2) | ||||||
Net cash used in investing activities | - | (2) | ||||||
Cash Flows From Financing Activities: | ||||||||
Proceeds from registered direct offering of common stock, | 1,450 | 2,944 | ||||||
Deferred offering costs from at-the-market transaction | (108) | (102) | ||||||
Proceeds from related party promissory note payable | 1,000 | - | ||||||
Net cash provided by financing activities | 2,342 | 2,842 | ||||||
Net decrease in cash | (908) | (943) | ||||||
Cash at beginning of year | 923 | 1,866 | ||||||
Cash at end of year | $ | 15 | $ | 923 | ||||
Supplemental disclosure of cash flow information: | ||||||||
Cash paid during the year for: | ||||||||
Interest | $ | 1 | $ | 2 | ||||
Supplemental schedule of non-cash investing and | ||||||||
Recognition of deferred offering costs as a reduction of | $ | 6 | $ | 23 |
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-reports-fourth-quarter-and-fiscal-2018-results-300819898.html
SOURCE MYOS RENS Technology
Copyright 2019 PR Newswire
1 Year MYOS RENS Technology Chart |
1 Month MYOS RENS Technology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions